

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hangauer et al.

Serial No. : 09/482,585

Filed : January 13, 2000

For : A NOVEL METHOD FOR DESIGNING  
PROTEIN KINASE INHIBITORS



Examiner:  
T. Prasthofer

Art Unit:  
1627

*File 7/10/01*  
*5/10/01*  
**RECEIVED**  
*14-01*

MAR 13 2001  
TECH CENTER 1600/2900

AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231  
**Box: Non-Fee Amendment**

Dear Sir:

In response to the January 30, 2001, office action, please amend the above-identified patent application as follows:

In the Specification:

Please substitute the paragraph at page 6, lines 12-13 with the following new paragraph:

*A1*  
Figure 5 demonstrates the binding interactions of src substrate Ac-Ile-Tyr-Gly-Glu-Phe-NH<sub>2</sub> (SEQ. ID. No. 1) in model src active site.

Please substitute ~~the~~ paragraph at page 13, line 31 to page 14, line 5 with the following new paragraph:

*A2*  
The standard pentapeptide sequence chosen for the majority of PKA inhibitors in Table 1 was derived from the pseudosubstrate sequence of the peptide inhibitor which was bound to PKA, when the crystal structure illustrated in Figure 1 was solved. The standard pentapeptide sequence used for src in Table 2, Ac-Ile-Xaa-Gly-Glu-Phe-NH<sub>2</sub> (SEQ. ID. No. 2), was described in Nair, Kim et al., 1995. Some of the chemistry used to prepare the PKA